AngioSoma, Inc. (SOAN) financial statements (2021 and earlier)

Company profile

Business Address 2500 WILCREST DRIVE, 3RD FLOOR
HOUSTON, TX 77042
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6681503349100105
Cash and cash equivalents6681503349100105
Inventory, net of allowances, customer advances and progress billings224040404040
Inventory224040404040
Prepaid expense 522312
Deferred costs  (12)(6)(3)  
Other undisclosed current assets  1263  
Total current assets:6989927692141146
Noncurrent Assets
Property, plant and equipment1111111
Other undisclosed noncurrent assets      12
Total noncurrent assets:11111113
TOTAL ASSETS:7090937793142159
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:144133133133133135138
Interest and dividends payable227227225225228228226
Other undisclosed accounts payable and accrued liabilities(83)(94)(91)(91)(94)(93)(88)
Debt215215173151175173231
Due to related parties11323311311311335160
Other undisclosed current liabilities287168295285289168458
Total current liabilities:759749715682710828887
Noncurrent Liabilities
Total liabilities:759749715682710828887
Stockholders' equity
Stockholders' equity attributable to parent, including:(689)(659)(621)(605)(617)(685)(728)
Common stock455436383304210170109
Additional paid in capital6,1936,1186,0356,0426,0061,2252,688
Accumulated other comprehensive income      1
Accumulated deficit(7,340)(7,215)(7,041)(6,953)(6,835)(6,674)(6,518)
Other undisclosed stockholders' equity attributable to parent222224,5922,992
Total stockholders' equity:(689)(659)(621)(605)(617)(685)(728)
TOTAL LIABILITIES AND EQUITY:7090937793142159

Income statement (P&L) ($ in thousands)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
Revenues    000
Cost of revenue
(Cost of Goods and Services Sold)
 (38)  (0)(0)(0)
Gross profit: (38)  000
Operating expenses(60)(92)(49)(51)(74)(62)(54)
Operating loss:(60)(129)(49)(51)(74)(62)(54)
Nonoperating income (expense)(64)193(39) (87)26553
Other nonoperating expense(64) (39) (87)  
Interest and debt expense(64)(45)(39)(67)(87)(212)(5)
Net income (loss):(188)19(127)(118)(248)(9)(5)
Other undisclosed net income (loss) attributable to parent64(193)39 87(147)5
Net loss attributable to parent:(124)(174)(88)(118)(161)(156)(1)
Other undisclosed net loss available to common stockholders, basic     (1,600) 
Net loss available to common stockholders, diluted:(124)(174)(88)(118)(161)(1,756)(1)

Comprehensive Income ($ in thousands)

12/31/2020
Q1
9/30/2020
Q4
6/30/2020
Q3
3/31/2020
Q2
12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
Net income (loss):(188)19(127)(118)(248)(9)(5)
Comprehensive income (loss):(188)19(127)(118)(248)(9)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent     (148)5
Comprehensive income (loss), net of tax, attributable to parent:(188)19(127)(118)(248)(157)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: